La cadena de opciones muestra datos clave de las opciones de acciones de STAR ASIA INVT CORP by STAR ASIA INVT CORP. a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para STAR ASIA INVT CORP by STAR ASIA INVT CORP...

STAR ASIA INVT CORP by STAR ASIA INVT CORP. (OTC:SIACF) Bolsa, Cadena de Opciones

STAR ASIA INVT CORP by STAR ASIA INVT CORP.

NASA is conducting a visiting vehicle study in coordination with SpaceX to gauge the possible impact of deploying <a href="https://www.benzinga.com/topic/starlink">Starlink satellites</a> closer to Earth and below the International Space Station on travel to and from the station, the space agency wrote to the Federal Communication Commission (FCC) on Tuesday.
What Happened: The study will assess the impact of deploying Starlink satellites closer to Earth upon transport to and from the ISS and ensure that the right number of satellites are deployed at a lower altitude. 
However, NASA also expressed its support for deploying 400 Starlink satellites initially closer to Earth. 
&#8220;Given the progress made and the continued positive collaboration between SpaceX and NASA, NASA supports FCC action that would allow SpaceX to initially operate 400 satellites continuously in the 300 km orbital shells,&#8221; NASA wrote in its letter.
&#8220;Upon the completion of the study, NASA will recommend any changes to the number of satellites it endorses at a lowered altitude.&#8221;
Why It Matters: Starlink is a segment of SpaceX that provides broadband to customers around the globe with the help of satellites in low-Earth orbit. 
SpaceX <a href="https://www.benzinga.com/news/24/10/41324450/elon-musk-says-spacexs-next-generation-starlink-satellites-will-be-so-big-that-only-starship-can-lau">requested the FCC for authority to lower the altitude</a> of its next-generation Starlink satellites, bringing them closer to Earth, earlier this month. Reduced altitude, SpaceX CEO Elon Musk then said, will allow for reduced latency. 
"The next generation Starlink satellites, which are so big that only Starship can launch them, will allow for a 10X increase in bandwidth and, with the reduced altitude, faster latency," <a href="https://www.benzinga.com/news/24/10/41449080/elon-musk-says-starlink-will-improve-significantly-with-multi-gigabit-bandwidth-after-spacexs-starsh">Musk wrote</a> on social media platform X. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41617327/lucid-to-start-taking-orders-for-gravity-suv-next-week-but-only-for-premium-variant-priced-at-about" target="_blank" rel="noreferrer noopener">Lucid To Start Taking Orders for Gravity SUV Next Week, But Only For Premium Variant Priced At About $95,000</a></li>
</ul>
Photo courtesy: Wikimedia

News

SPACE

Tech

NASA Endorses Initial Deployment Of 400 Starlink Satellites Closer To Earth, Will Conduct Study To Gauge Impact On Travel To And From ISS

Milestone Achievement Supports Planned FDA Submission of DeepView AI&#xAE;-Burn in 2025
DALLAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the final group of burn center patients in the Company's U.S. Burn Pivotal Study have successfully completed their clinical visits.
One of the largest domestic burn center studies ever conducted, the U.S. Burn Pivotal Study is expected to be the final clinical trial before the Company seeks U.S. Food and Drug Administration ("FDA") approval of its DeepView&#xAE; System for burn indication ("DeepView AI&#xAE;-Burn") in the first half of 2025. DeepView AI&#xAE;-Burn is a non-invasive, predictive medical device designed to distinguish between healing and non-healing tissue in order to provide clinicians with an immediate and binary assessment of a burn wound's healing potential.
The Company expects to report topline results from this study in December 2024.

MDAI

Spectral AI Announces Last Patient Out In U.S. Burn Pivotal Study At Burn Centers; Milestone Achievement Supports Planned FDA Submission Of DeepView AI-Burn In 2025

DATS

DatChat's Dragon Interact Subsidiary Acquires RPM Interactive In Consideration For The Issuance Of 3.5M Shares Of Common Stock

<ul>
<li>Revenue: $24.9 billion to $25.5 billion</li>
<li>GAAP EPS: $1.77 to $1.89</li>
<li>Adjusted EPS: $2.39 to $2.51</li>
</ul>

Guidance

FLEX

Flex Revised FY25 Outlook For Revenues To $24.9B-$25.5B (From $25.4B-$26.4B) Vs. $25.78B Estimate, Adjusted EPS To $2.39-$2.51 (From $2.30-$2.50) Vs. $2.41 Estimate

B of A Securities analyst Julien Dumoulin-Smith maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Buy and lowers the price target from $321 to $269.

Price Target

Analyst Ratings

FSLR

B of A Securities Maintains Buy on First Solar, Lowers Price Target to $269

Needham analyst James Ricchiuti maintains CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) with a Buy and lowers the price target from $35 to $33.

CECO

Needham Maintains Buy on CECO Environmental, Lowers Price Target to $33

Avnet Sees Q2 Sales Of $5.40B-$5.70B Vs. $5.5B Estimate; Projects Diluted EPS Of $0.80-$0.90 Vs. $1.01 Estimate

Barclays analyst Ross Sandler maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) with a Overweight and raises the price target from $200 to $220.

GOOG

Barclays Maintains Overweight on Alphabet, Raises Price Target to $220

GDEV Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEV#NASDAQ">GDEV</a>), an international gaming and entertainment company ("GDEV" or the "Company"), announces changes to its Board of Directors and executive leadership team as part of its ongoing strategy to enhance operational efficiency and support its global growth ambitions.
Olga Loskutova, who has served as an Independent Director on GDEV's Board since 2022, will be stepping down from her position on the Board of Directors to assume the role of Chief Operating Officer (COO) of GDEV. Olga brings with her a wealth of experience in global business and general management, positioning her to provide management, leadership, and vision to guide GDEV Inc. towards meeting both its short-term and long-term strategic goals.
Following Olga's transition, GDEV's Board will consist of six members, with four remaining independent directors. In addition, Olga's seat on the Nomination and Compensation Committee, on which she previously served, has been assumed by current independent director Tal Shoham.

Management

GDEV

GDEV Announces Olga Loskutova Will Be Stepping Down From Her Position On The Board Of Directors To Assume The Role Of Chief Operating Officer

WIIM

THRY

Thryv Holdings shares are trading lower after the company reported preliminary Q3 results. Also, the company announced a $75 million public offering and announced the proposed acquisition of Keap.

Biotech

General

MLYS

Mineralys Therapeutics Completes Early Enrollment In Second Pivotal Trial For Lorundrostat In Hypertension; Topline Data Expected In Mid First Half Of 2025, With Virtual KOL Event To Discuss Unmet Need And Clinical Program

Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) raises FY2024 Adj EPS guidance from $1.29-1.35 to $1.33-1.37 vs $1.31 analyst estimate. Narrows FY2024 sales outlook from $3.44 billion-3.51 billion to $3.44 billion-3.47 billion vs $3.41 billion estimate.

GTES

Gates Industrial Corp Raises FY2024 Adj EPS Guidance from $1.29-1.35 to $1.33-1.37 vs $1.31 Est; Core Sales growth of -4 to -3%.

B of A Securities analyst Justin Post maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Neutral and raises the price target from $84 to $99.

RDDT

B of A Securities Maintains Neutral on Reddit, Raises Price Target to $99

Biomarker cohort for delpacibart braxlosiran (del-brax), the first potential therapy to target DUX4, is measuring changes in DUX4 regulated biomarkers; del-brax 2 mg/kg will be administered every six weeks
Enrollment in the del-brax biomarker cohort expected to be completed in 1H 2025; on track to initiate del-brax functional cohort in 1H 2025
In previously reported initial data, del-brax 2 mg/kg every six weeks showed unprecedented and consistent reductions of DUX4 regulated genes, significant decreases in novel circulating biomarker and creatine kinase, and trends of functional improvement at the four-month timepoint
SAN DIEGO, Oct. 30, 2024 /PRNewswire/ --&nbsp;Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs&#x2122;), today announced the initiation of a biomarker cohort in the Phase 1/2&nbsp; FORTITUDE&#x2122; trial of delpacibart braxlosiran (del-brax/AOC 1020) in people living with facioscapulohumeral muscular dystrophy (FSHD). Avidity is pursuing a potential accelerated approval path for del-brax and expects enrollment in the biomarker cohort to be completed in the first half of 2025. Avidity also remains on track to initiate a functional cohort in the first half of 2025. In addition, enrollment of the FORTITUDE Open-label Extension study (OLE) is ongoing.

Avidity Biosciences Pursues Potential Accelerated Approval Path With Initiation Of Biomarker Cohort In FORTITUDE Trial For Delpacibart Braxlosiran In People Living With Facioscapulohumeral Muscular Dystrophy

Flex Sees Q3 Revenues Of $6.0B-$6.4B Vs. $6.5B Estimate, Adjusted EPS Of $0.60-$0.66 Vs. $0.56 Estimate

Trinity Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIN#NASDAQ">TRIN</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is a 5.45 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $61.77 million which beat the analyst consensus estimate of $55.53 million by 11.23 percent. This is a 33.01 percent increase over sales of $46.44 million the same period last year.

Earnings

Earnings Beats

TRIN

Trinity Cap Q3 EPS $0.52, Inline, Sales $61.77M Beat $55.53M Estimate

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement
Initiation of Phase 1b clinical trial in Alzheimer's disease patients planned for year-end 2024
&nbsp;
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Oct. 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented positive results from all five cohorts from the Phase 1a, single ascending dose clinical trial of its lead product candidate, PMN310, at the 17th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place from October 29 – November 1, 2024 in Madrid, Spain.
PMN310 is an investigational humanized monoclonal antibody (mAb) designed and developed to selectively target soluble amyloid beta oligomers (AβOs), which ProMIS believes to be the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques.

ProMIS Neurosciences Presents Data From PMN310 Phase1a Clinical Trial At The 17th Clinical Trials On Alzheimer's Disease Conference; Results Indicated PMN310 Was Generally Well-Tolerated And Monthly Dosing Can Provide CSF Levels Adequate For Target Engagement

B of A Securities analyst Tal Liani downgrades Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) from Buy to Neutral and lowers the price target from $205 to $195.

Downgrades

CHKP

B of A Securities Downgrades Check Point Software to Neutral, Lowers Price Target to $195

Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) reported $1.26 million in sales this quarter.

ABTS

Abits Group Q3 Sales $1.26M

PSNY

TSLA

Polestar Expands Charging Access With 17,800 Tesla Superchargers In North America And Over 850,000 Charging Points Across Europe, Enhancing Global EV Charging Network

Comments

STAR ASIA INVT CORP by STAR ASIA INVT CORP.

STAR ASIA INVT CORP by STAR ASIA INVT CORP. (SIACF) Opciones

Loading...

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL